Literature DB >> 7491701

Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients.

M Brytting1, M Mousavi-Jazi, L Boström, M Larsson, J Lunderberg, P Ljungman, O Ringdén, V A Sundqvist.   

Abstract

Granulocytes, monocytes, and T- and B-lymphocytes were separated from 28 blood samples collected from 5 bone marrow transplant (BMT) recipients. About 40% of granulocyte, monocyte, and B-lymphocyte samples were CMV DNA-positive by polymerase chain reaction in recipients with cytomegalovirus (CMV) infection. CMV DNA was rarely detected in separated T-lymphocytes. Within each of the simultaneously separated paired samples, there were several with single positive cell subtypes. Monocytes, granulocytes, and B-lymphocytes were the single positive samples in some instances. Thus, it is important to have all of the different cell subtypes present in samples for detection of CMV DNA in peripheral blood. We also studied the appearance of CMV DNA in plasma and peripheral blood leukocytes (PBLs) from 351 blood samples collected from 30 BMT recipients during a follow-up period of at least 3 months after BMT. All cell subtypes were represented in the PBL samples. In the 13 recipients who developed symptoms possibly associated with CMV infection or CMV disease, a correlation with the detection of CMV DNA in < or = 2 x 10(5) PBLs was found. In PBLs from 11 of the 13 BMT recipients, CMV DNA was detected before the onset of symptoms. CMV DNA was not detected in < or = 2 x 10(5) PBLs from recipients without CMV infection. The virus load in PBLs decreased during ganciclovir treatment. Nine of the 13 recipients displayed PCR-positive plasma samples, and CMV DNA was detected frequently after the onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491701

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Enhanced analytical sensitivity of a quantitative PCR for CMV using a modified nucleic-acid extraction procedure.

Authors:  A Ferreira-Gonzalez; S Yanovich; M R Langley; L A Weymouth; D S Wilkinson; C T Garrett
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients.

Authors:  G M Gallez-Hawkins; B R Tegtmeier; A ter Veer; J C Niland; S J Forman; J A Zaia
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

Review 3.  Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

Authors:  H Hebart; L Kanz; G Jahn; H Einsele
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

4.  Detection of CMV DNA in bone marrow transplant recipients: plasma versus leucocyte polymerase chain reaction.

Authors:  P C Woo; S K Lo; K Y Yuen; J S Peiris; H Siau; E K Chiu; R H Liang; T K Chan
Journal:  J Clin Pathol       Date:  1997-03       Impact factor: 3.411

Review 5.  Humanized mouse models of human cytomegalovirus infection.

Authors:  Lindsey B Crawford; Daniel N Streblow; Morgan Hakki; Jay A Nelson; Patrizia Caposio
Journal:  Curr Opin Virol       Date:  2015-06-25       Impact factor: 7.090

6.  Nested polymerase chain reaction in the diagnosis of congenital cytomegalovirus infection.

Authors:  R Sivakumar; N Singh; S Singh
Journal:  Indian J Pediatr       Date:  2001-11       Impact factor: 1.967

7.  Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene.

Authors:  J Vieira; T J Schall; L Corey; A P Geballe
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  Monitoring of cytomegalovirus infection in non-transplant pediatric acute lymphoblastic leukemia patients during chemotherapy.

Authors:  Nonthapan Phasuk; Jiraporn Keatkla; Sasivimol Rattanasiri; Chonnamet Techasaensiri; Usanarat Anurathapan; Nopporn Apiwattanakul
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.